Ingrezza Miss Takes Neurocrine Biosciences (NBIX) PT Down To $110 At Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neurocrine Bio. (NBIX) PT Lowered to $102 at H.C. Wainwright
December 13, 2018 11:09 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $102.00 (from $162.00) while maintaining a Buy rating.
... MoreNeurocrine Bio. (NBIX) PT Lowered to $105 at Oppenheimer
December 13, 2018 9:30 AM ESTOppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $140.00) while maintaining a Outperform rating.
Olson commented, "T-Force-GOLD missed the primary endpoint, sending NBIX shares down 14% on 12/12 (vs. NBI +1.3% and S&P 500 +0.5%) on the loss of this important... More
